CN116425756B - 腺苷受体拮抗剂化合物及其应用 - Google Patents

腺苷受体拮抗剂化合物及其应用 Download PDF

Info

Publication number
CN116425756B
CN116425756B CN202211456336.XA CN202211456336A CN116425756B CN 116425756 B CN116425756 B CN 116425756B CN 202211456336 A CN202211456336 A CN 202211456336A CN 116425756 B CN116425756 B CN 116425756B
Authority
CN
China
Prior art keywords
compound
amino
substituted
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211456336.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN116425756A (zh
Inventor
Y-S·李
S-W·权
K－S·金
J-G·金
J-A·金
A-N·文
S-Y·朴
J-S·潘
D-K·宋
J-Y·郑
S-J·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ildong Pharmaceutical Co Ltd
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of CN116425756A publication Critical patent/CN116425756A/zh
Application granted granted Critical
Publication of CN116425756B publication Critical patent/CN116425756B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CN202211456336.XA 2019-11-19 2020-11-19 腺苷受体拮抗剂化合物及其应用 Active CN116425756B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2019-0149117 2019-11-19
KR1020190149117A KR20210061202A (ko) 2019-11-19 2019-11-19 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
CN202080080922.1A CN114829363B (zh) 2019-11-19 2020-11-19 腺苷受体拮抗剂化合物
PCT/IB2020/000971 WO2021099838A1 (en) 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080080922.1A Division CN114829363B (zh) 2019-11-19 2020-11-19 腺苷受体拮抗剂化合物

Publications (2)

Publication Number Publication Date
CN116425756A CN116425756A (zh) 2023-07-14
CN116425756B true CN116425756B (zh) 2025-05-13

Family

ID=75980093

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211456336.XA Active CN116425756B (zh) 2019-11-19 2020-11-19 腺苷受体拮抗剂化合物及其应用
CN202080080922.1A Active CN114829363B (zh) 2019-11-19 2020-11-19 腺苷受体拮抗剂化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080080922.1A Active CN114829363B (zh) 2019-11-19 2020-11-19 腺苷受体拮抗剂化合物

Country Status (14)

Country Link
US (1) US12606564B2 (https=)
EP (1) EP4061817A4 (https=)
JP (2) JP7681616B2 (https=)
KR (3) KR20210061202A (https=)
CN (2) CN116425756B (https=)
AU (2) AU2020386189B2 (https=)
BR (2) BR122023020015A2 (https=)
CA (1) CA3158731A1 (https=)
CL (1) CL2022001307A1 (https=)
IL (1) IL293107A (https=)
MX (1) MX2022005976A (https=)
PH (1) PH12022551223A1 (https=)
TW (3) TWI850492B (https=)
WO (3) WO2021099832A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TW202508599A (zh) * 2023-05-19 2025-03-01 南韓商尹諾衛醫藥有限公司 用於神經保護或治療α突觸核蛋白及/或神經發炎相關疾病的化合物
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025170158A1 (ko) * 2024-02-08 2025-08-14 아이리드비엠에스 주식회사 Cxcr7 수용체 조절제 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1349857B1 (en) * 2001-01-10 2010-06-16 Vernalis Research Limited Purine derivatives as purinergic receptor antagonists
WO2011050160A1 (en) * 2009-10-22 2011-04-28 Biogen Idec Ma Inc. Pharmaceuticals, compositions and methods of making and using the same
CN102076692A (zh) * 2008-06-25 2011-05-25 弗纳里斯研究有限公司 三唑并[4，5-d]嘧啶衍生物及其作为嘌呤受体拮抗剂的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507552A (ja) * 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
PL337888A1 (en) * 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
ATE520694T1 (de) 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US20060128956A1 (en) * 2003-04-21 2006-06-15 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (Purin-6-yl) amino acid and production method thereof
US8557830B2 (en) * 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
JP7337502B2 (ja) 2015-09-16 2023-09-04 ロクソ オンコロジー， インコーポレイテッド がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
DE102017125533A1 (de) 2017-10-31 2019-05-02 Helmholtz-Zentrum Dresden - Rossendorf E.V. 4-(Furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amin-Derivate und deren Verwendung
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP4368184A3 (en) 2019-11-19 2024-07-31 Modag GmbH Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
AU2020389474B2 (en) 2019-11-19 2026-03-12 Clariant International Ltd Solvates of abscisic acid and liquid compositions containing abscisic acid
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1349857B1 (en) * 2001-01-10 2010-06-16 Vernalis Research Limited Purine derivatives as purinergic receptor antagonists
CN102076692A (zh) * 2008-06-25 2011-05-25 弗纳里斯研究有限公司 三唑并[4，5-d]嘧啶衍生物及其作为嘌呤受体拮抗剂的应用
WO2011050160A1 (en) * 2009-10-22 2011-04-28 Biogen Idec Ma Inc. Pharmaceuticals, compositions and methods of making and using the same

Also Published As

Publication number Publication date
WO2021099838A9 (en) 2021-09-30
CN116425756A (zh) 2023-07-14
WO2021099832A2 (en) 2021-05-27
AU2023202886B2 (en) 2024-11-14
KR102752564B1 (ko) 2025-01-14
KR20210061202A (ko) 2021-05-27
AU2023202886A1 (en) 2023-05-25
KR20220104760A (ko) 2022-07-26
TW202342481A (zh) 2023-11-01
US12606564B2 (en) 2026-04-21
WO2021099838A1 (en) 2021-05-27
BR122023020015A2 (pt) 2024-02-27
TWI851336B (zh) 2024-08-01
US20230159534A1 (en) 2023-05-25
KR102749480B1 (ko) 2025-01-07
WO2021099837A1 (en) 2021-05-27
AU2020386189A1 (en) 2022-06-02
JP2023505915A (ja) 2023-02-13
TW202132304A (zh) 2021-09-01
BR112022009487A2 (pt) 2023-02-23
TW202132305A (zh) 2021-09-01
CA3158731A1 (en) 2021-05-27
JP2025120182A (ja) 2025-08-15
KR20240148969A (ko) 2024-10-11
AU2020386189B2 (en) 2024-05-16
CL2022001307A1 (es) 2023-03-03
WO2021099832A3 (en) 2021-07-01
JP7681616B2 (ja) 2025-05-22
PH12022551223A1 (en) 2023-07-17
MX2022005976A (es) 2022-08-18
TWI850492B (zh) 2024-08-01
IL293107A (en) 2022-07-01
CN114829363B (zh) 2024-10-01
EP4061817A4 (en) 2023-11-01
CN114829363A (zh) 2022-07-29
EP4061817A1 (en) 2022-09-28
WO2021099838A8 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
CN116425756B (zh) 腺苷受体拮抗剂化合物及其应用
AU2012319549B2 (en) Pyrazoloquinoline derivative
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
JP7797486B2 (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
KR20130116358A (ko) Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
JP7777596B2 (ja) Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
KR20210126051A (ko) Cd73 억제제, 그 제조 방법 및 용도
JP2019500389A (ja) 窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用
CN117043163A (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
HK40077081A (en) Adenosine receptor antagonist compounds
HK40097385A (zh) 腺苷受体拮抗剂化合物及其应用
EA050210B1 (ru) Соединения-антагонисты аденозиновых рецепторов
EA051725B1 (ru) Соединения-антагонисты аденозиновых рецепторов
EP4590396A1 (en) Pcsk9 inhibitors and methods of use thereof
CN120774920A (zh) PI3Kδ-mTOR双靶点抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40097385

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant